Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/07/2009US7514566 Thiazole compounds and methods of use
04/07/2009US7514565 3,5-Difluoropyridines
04/07/2009US7514564 Substituted amine derivatives and methods of use
04/07/2009US7514562 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
04/07/2009US7514561 Pesticidal 5-(acylamino) pyrazole derivatives
04/07/2009US7514560 Thermodynamically stable at room temperature, nonhygroscopic
04/07/2009US7514558 e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary disease; asthma
04/07/2009US7514557 Hepatitis C; preparing 8-bromo-7-alkoxyquinolines 2-substituted with a hetercyclic ring having an amine, carbamate, amine or urea group an 4-substituted with a 3-prolineoxy- group or derivative; intermediates
04/07/2009US7514555 Compounds for the treatment of metabolic disorders
04/07/2009US7514550 Sense and antisense regions; kits for gene silencing
04/07/2009US7514548 Methods of inhibiting COX-2
04/07/2009US7514543 Immunoglobulin fusion for use as therapeutic tool in prevention and treatment of chronic progression of atherosclerosis in diabetic patients
04/07/2009US7514541 crosslinking with curing agents in acidic or alkaline conditions, to form to products used in cosmetic, medical and pharmaceutical applications
04/07/2009US7514538 Compositions and methods for the diagnosis and treatment of tumor
04/07/2009US7514530 Peptide carrier for delivering siRNA into mammalian cells
04/07/2009US7514475 Benzylamine analogues
04/07/2009US7514474 Prostaglandin analog compositions and methods to treat epithelial-related conditions
04/07/2009US7514473 Calcium receptor antagonist; (E)-3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-acrylic acid hydrochloride; bone disorders; hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing, arthritis, Paget's disease, humoral hypercalcemia, osteoporosis
04/07/2009US7514472 Fat or oil composition
04/07/2009US7514471 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance
04/07/2009US7514470 Aniline derivatives as selective androgen receptor modulators
04/07/2009US7514469 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse
04/07/2009US7514468 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
04/07/2009US7514467 Novel polymorphic form IV and solvate; precipitation from ethyl acetate
04/07/2009US7514466 Purification of progesterone receptor modulators
04/07/2009US7514465 selective inhibitor of protease activated receptor (PAR)-4-dependent activation; inhibits low thrombin-induced Ca++ signal and thromboxane production; inhibit vascular endothelial growth factor induced cell proliferation, migration, tube formation in human umbilial vein endothelial cells; antitumor agent
04/07/2009US7514464 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; Extended duration of action for at least 28 days
04/07/2009US7514463 Lonidamine analogues and their use in male contraception and cancer treatment
04/07/2009US7514462 ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
04/07/2009US7514461 Chroman derivatives
04/07/2009US7514460 Benzazole analogues and uses thereof
04/07/2009US7514459 Gamma-secretase inhibitors
04/07/2009US7514458 Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease
04/07/2009US7514457 Substituted aryloxymethyl bicyclicmethyl acetamide compounds
04/07/2009US7514456 Nicotinamide derivatives useful as p38 inhibitors
04/07/2009US7514455 Derivatives of 2-pyridinol or its tautomer 2-pyridone; microorganism comprising Penicillium sp. FO-125 FERM BP-8048; antifungal antibiotics
04/07/2009US7514454 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
04/07/2009US7514453 Method for enhancing mutant protein activity
04/07/2009US7514452 3-(4-hexylphenyl)-2-furancarboxylic acid 2-(4-hydroxy-3-nitrobenzoyl)hydrazide; nonpeptidergic glucagon receptor antagonist; orally; decrease blood sugar levels; hypoglycemic agent; dabetes mellitus type I and II, obesity, hyperlipidemia, gastrointestinal disorders
04/07/2009US7514451 1 -cyclopropyl-7- [3-cyclopropylaminomethyl-4-fluoro-1 -pyrrolidinyl]-6-fluoro -1 ,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid; bactericide; against drug-resistant bacteria and against gram-positive bacteria, such as MRSA, PRSP and VRE
04/07/2009US7514450 Azabicyclic aryl derivatives
04/07/2009US7514449 inhibitor of activated blood coagulation factor X; N-(5-chloropyridin-2-yl)-3- {[(trans-4-pyrrolidin-1 -ylcyclohexyl)carbonyl]aznino}furo[3,2-c]pyridine-2-carboxaxnide; disorders caused by thrombi and emboli in a mammal; decreased toxicity, and causes few side effects
04/07/2009US7514448 Azaindoles useful as inhibitors of rock and other protein kinases
04/07/2009US7514447 e.g. [2-(4-Isopropyl-piperazin-1-yl)-benzooxazol-6-yl]-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-amine; C-kit kinase receptor or stem cell factor inhibitors; anticarcinogenic agents; veterinary medicine
04/07/2009US7514446 antineoplastic/antimitotic agents; inhibit proliferation of the cell; breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma; Polo-like kinase inhibitors; 2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride
04/07/2009US7514445 Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
04/07/2009US7514444 compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told
04/07/2009US7514443 pyrazolo- and imidazo-pyrimidine derivatives; for anxiety and pain, neurodegenerative disorders; 8-Pyridin-4-yl-4-trifluoromethyl-2-(4-trifluoromethyl-phenyl)-imidazo[1,5-a]pyrimidine
04/07/2009US7514442 Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
04/07/2009US7514441 Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents
04/07/2009US7514440 angiogenesis inhibitors; as antitumor agents; kinase inhibitors like vascular endothelial growth factor receptors antagonists
04/07/2009US7514439 Oxime derivative and preparations thereof
04/07/2009US7514438 Melanin concentrating hormone receptor antagonist
04/07/2009US7514437 2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N,N-dimethylethanamide; to suppress uterine contractions; cyclization of leucine analogs
04/07/2009US7514436 Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators
04/07/2009US7514435 Pyrrolotriazine kinase inhibitors
04/07/2009US7514434 To inhibit replication and/or proliferation of Hepatitis C virus; viral infections; 5-Dichloromethyl-3-[4-[3'-(2',6'-dichlorophenyl)-5'-isoxazolyl]phenyl]-1,2,4-oxadiazole
04/07/2009US7514433 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
04/07/2009US7514432 5-[5-(Benzo[b]thiophen-7-yloxy)-pentyloxy]-2-(tetrahydro-pyran-2-yloxymethyl)-4H-pyran-4-one; antiproliferative and antiangiogenic activities; to treat cancers (such as leukemia), ocular diseases and arthritis; excellent bioavailability and pharmacokinetic properties
04/07/2009US7514431 Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
04/07/2009US7514430 Nitrogen compounds such as N-phenyl-N'-{(1R,2S)-2-[(2S)-2-benzyl-6-oxo-morpholin-4-yl-methyl]-cyclohexyl }-urea, used to control chemotactic cytokines, and administered for the prevention of asthma or allergies; inhibition of the migration of eosinophils
04/07/2009US7514429 Benzoxazinone-derived compounds, their preparation and use as medicaments
04/07/2009US7514427 Aids therapy; viricides
04/07/2009US7514426 Substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives
04/07/2009US7514425 Short-acting sedative hypnotic agents for anesthesia and sedation
04/07/2009US7514424 schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, visceral pain, neurogenic inflammation, asthma, micturition disorders such as urinary incontinence and nociception; reductive hydrogenation
04/07/2009US7514423 Tricyclic mercaptoacetylamide derivatives; pyrido[1,2-a][2]benzazepine carboxylic acids;; glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, microalbuminuria and end stage renal disease; nondiabetic
04/07/2009US7514422 To treat obesity, schizophrenia, anxiety, depression, alcoholism; using 3-benoazepine compounds like 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin); serotonin 2c receptor agonists
04/07/2009US7514421 Using compounds such as 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N {(R)- alpha -[N ((R)-1-carboxy-2-methylthio -ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine for therapy of Irritable Bowel Syndrome
04/07/2009US7514420 Steroids having 1,8-unsaturation and formulations comprising same
04/07/2009US7514419 Phosphorus-containing thyromimetics
04/07/2009US7514418 silyl camptothecin derivatives for cancer and/or leukemia; cytotoxic; DNA-topoisomerase I inhibitors; antitumor agents; 7-trimethylsilyl-10-acetoxy camptothecin, 7-trimethylsilyl-11-fluoro camptothecin
04/07/2009US7514417 Therapy of tachycardia and atrial flutter, angina, and myocardial infarction using compounds such as -(6-[((3R)oxolan-3-yl)amino]-2-{4-[4-(trifluoromethyl)phenyl]pyrazolyl}purin-9-yl)(4S,2R,3R,5R)-5-(hydroxymethyl)oxolane-3,4-diol
04/07/2009US7514416 Suppressing growth of pancreatic tumors or cancer cells having a K-ras gene point mutation by administering directly to the tumor cells an adenoviral vector having a DNA sequence encoding human interferon alpha and linked to a promoter and an antisense K-ras expressing vector
04/07/2009US7514415 Suppressing an immune response in rheumatoid arthritis by administering a pure or isolated oligodeoxynucleotide of up to 100 nucleotides in length along with an additional antiinflammatory agent, immunosuppressive agent or antiarthritis agent
04/07/2009US7514414 Autoimmune disease; bactericides, viricides, fungicides, parasiticides
04/07/2009US7514413 Combination of ATP-depleting agents (mitochondrial ATP-inhibitor, a methylthioadenosine phosphorylase inhibitor or an inhibitor of De Novo purine synthesis); chemotherapy
04/07/2009US7514412 Anticancer biangeloyl saponins
04/07/2009US7514411 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
04/07/2009US7514406 For treatment of cancers through activation of silenced tumor suppressor genes, promotion of apoptosis in cancerous cells, and inhibition of transcriptional repressor activity in oncogenes; drug screening
04/07/2009US7514405 Method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable
04/07/2009US7514402 Comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein; brain disorders; kits; efficiently target and deliver substances
04/07/2009US7514244 Nutrients and nutraceuticals obtained from cultures of microorganisms, then recovering and using as feeds for infants
04/07/2009US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders
04/07/2009US7514225 detecting drugs that inhibits the binding of macrophage migration inhibitory factor (MIF) to an antimacrophage migration inhibitor factor monoclonal or polyclonal antibody; drug screening
04/07/2009US7514107 Treatment of diseases involving defective gap junctional communication
04/07/2009US7514105 Bioavailability/bioefficacy enhancing activity of Cuminum cyminum and extracts and fractions thereof
04/07/2009US7514100 Controlled release hydrocodone formulations
04/07/2009US7514099 Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
04/07/2009US7514098 Use of targeted cross-linked nanoparticles for in vivo gene delivery
04/07/2009US7514097 Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same
04/07/2009US7514096 Triacylglycerols of enriched CLA content
04/07/2009US7514095 Three-dimensional chitosan matrix or drug release; tissue engineering ; water in oil emulsion containing active materials; extrusion; coagulation
04/07/2009US7514094 Synergistic mixture of N-cyanomethyl-4-trifluoromethyl-3-pyridinecarboxyamide and insecticides such as Pirimicarb, and Clothianidin; killing pests grown in some place by one time and reducing a dosage than in a case of using an effective component respectively alone
04/07/2009US7514091 Aminated silicone detergent cosmetic composition and use
04/07/2009US7514087 Administering primer and boosting composition comprising source of one or more CD8+ T cell epitopes of melanoma from a source of non-replicating or replication-deficient recombinant poxvirus vector in the human
04/07/2009US7514070 Method for exfoliating skin
04/07/2009US7514068 Biphenyl-pyrazolecarboxamide compounds
04/07/2009CA2544460C Controlled-release biocompatible ocular drug delivery implant devices and methods
04/07/2009CA2527366C A method of promoting sleep using topical administration of vasoactive agents